Skip to main content
. 2009 May 27;83(16):7982–7995. doi: 10.1128/JVI.00259-09

FIG. 1.

FIG. 1.

U18666A treatment of cells causes cholesterol accumulation and inhibits HIV-1 production. (A) LuSIV cells were untreated or treated with U18666A at the concentrations indicated. The cells were stained with filipin and examined by fluorescence microscopy to determine cholesterol phenotypic changes. Scale bars represent 20 μm. (B) LuSIV cells were untreated or treated with U18666A at the concentrations indicated for 24 h and then exposed to 10 ng of HIV-1MN for 48 h in the presence of the compound at the pretreatment concentration. Virus production was measured using a luciferase assay. The data shown represent the mean ± standard deviation from three independent experiments. *, P < 0.05; **, P < 0.001, compared to cells without U18666A treatment. TZM-bl cells were untreated or treated with U18666A at the indicated concentrations and exposed to X4-tropic HIV-1MN (3.125 to 100 ng p24/2 × 104 cells) (C) or R5-tropic HIV-1BaL (8.75 to 140 ng p24/2 × 104 cells) (D) for 48 h in the presence of the compound at the pretreatment concentration. Virus replication was measured using a luciferase assay. The data shown represent the mean ± standard deviation from three independent experiments.